Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Swiss National Bank

Swiss National Bank lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 570,200 shares of the medical equipment provider’s stock after selling 29,000 shares during the quarter. Swiss National Bank owned 0.29% of Zimmer Biomet worth $56,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $204,000. Sivia Capital Partners LLC bought a new stake in Zimmer Biomet during the second quarter worth approximately $232,000. United Bank boosted its holdings in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares in the last quarter. Savant Capital LLC grew its position in Zimmer Biomet by 73.3% in the second quarter. Savant Capital LLC now owns 7,185 shares of the medical equipment provider’s stock worth $655,000 after buying an additional 3,039 shares during the last quarter. Finally, Penserra Capital Management LLC grew its position in Zimmer Biomet by 39.9% in the second quarter. Penserra Capital Management LLC now owns 4,733 shares of the medical equipment provider’s stock worth $431,000 after buying an additional 1,350 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZBH. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Wells Fargo & Company boosted their target price on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. Finally, Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $94.00 to $120.00 in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Trading Up 2.3%

NYSE ZBH opened at $93.82 on Thursday. The firm’s 50 day moving average price is $92.28 and its two-hundred day moving average price is $95.40. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The stock has a market cap of $18.36 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 1.87 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same quarter in the prior year, the company earned $2.31 earnings per share. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.